

FOI 2417

16th May 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Response:

Adalimumab – Humira	33
Adalimumab Biosimilar	273
Apremilast	0
Bimekizumab	4
Brodalumab	7
Certolizumab	7
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept – Enbrel	1
Etanercept Biosimilar	2
Guselkumab	62
Infliximab – Remicade	0
Infliximab Biosimilar	7
Ixekizumab	106
Risankizumab	64
Secukinumab	29
Tildrakizumab	8
Ustekinumab	27

Question 2: How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Response:

Adalimumab – Humira	22
Adalimumab Biosimilar	47
Bimekizumab	1
Certolizumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	4
Secukinumab	1
Ustekinumab	0

Email: FOI.team@southerntrust.hscni.net